EGFR Resisters on Twitter

Great talk Dr John Heymach #oligometastatic #nsclc challenges all to rethink #OMD: don't need to refine definition, we need to predict who benefits
Counting mets isn't enough, need multidimensional approach to include, biology, response to Rx &
% consolidatability.
#WCLC22 #LCSM https://t.co/LKQ7SaLTAa
EGFRResisters photo
OS isn't the only impt endpoint for patients!
All trials, esp #SCLC, need
👉PROs
👉QOL endpt/compare UPFRONT/CONCURRENT #palliativecare
Dr Temel's data in #nsclc in 2010 shows ⬆️ BOTH QoL & survival
Sympts & AEs are tough- Pls help us live BETTER, not just longer!
#WCLC22 #LCSM https://t.co/8ukQkd3wQ0
August newsletter is out! Latest EGFR Lung Cancer Research, patient advocacy and more. #lungcancer https://t.co/gu4XyCTKsO https://t.co/LIQrORgKK4 EGFRResisters photo